Nothing Special   »   [go: up one dir, main page]

PL2794878T3 - Organizacja wektora ekspresyjnego, nowe sposoby generowania komórek produkcyjnych i ich zastosowanie do rekombinowanej produkcji polipeptydów - Google Patents

Organizacja wektora ekspresyjnego, nowe sposoby generowania komórek produkcyjnych i ich zastosowanie do rekombinowanej produkcji polipeptydów

Info

Publication number
PL2794878T3
PL2794878T3 PL12813822T PL12813822T PL2794878T3 PL 2794878 T3 PL2794878 T3 PL 2794878T3 PL 12813822 T PL12813822 T PL 12813822T PL 12813822 T PL12813822 T PL 12813822T PL 2794878 T3 PL2794878 T3 PL 2794878T3
Authority
PL
Poland
Prior art keywords
polypeptides
expression vector
cell generation
generation methods
production
Prior art date
Application number
PL12813822T
Other languages
English (en)
Inventor
Peter Michael HUELSMANN
Hendrik Knoetgen
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL2794878T3 publication Critical patent/PL2794878T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL12813822T 2011-12-22 2012-12-19 Organizacja wektora ekspresyjnego, nowe sposoby generowania komórek produkcyjnych i ich zastosowanie do rekombinowanej produkcji polipeptydów PL2794878T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11195363 2011-12-22
PCT/EP2012/076167 WO2013092723A1 (en) 2011-12-22 2012-12-19 Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
EP12813822.9A EP2794878B1 (en) 2011-12-22 2012-12-19 Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides

Publications (1)

Publication Number Publication Date
PL2794878T3 true PL2794878T3 (pl) 2020-07-27

Family

ID=47557065

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12813822T PL2794878T3 (pl) 2011-12-22 2012-12-19 Organizacja wektora ekspresyjnego, nowe sposoby generowania komórek produkcyjnych i ich zastosowanie do rekombinowanej produkcji polipeptydów

Country Status (16)

Country Link
US (3) US9963511B2 (pl)
EP (2) EP3816284A1 (pl)
JP (4) JP2015502165A (pl)
KR (3) KR102184059B1 (pl)
CN (2) CN107881196A (pl)
BR (1) BR112014012667A2 (pl)
CA (2) CA3125875A1 (pl)
ES (1) ES2791758T3 (pl)
HK (2) HK1203546A1 (pl)
HR (1) HRP20200744T1 (pl)
MX (1) MX355625B (pl)
PL (1) PL2794878T3 (pl)
RU (2) RU2628703C2 (pl)
SG (3) SG11201403223PA (pl)
SI (1) SI2794878T1 (pl)
WO (1) WO2013092723A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2794878T3 (pl) 2011-12-22 2020-07-27 F.Hoffmann-La Roche Ag Organizacja wektora ekspresyjnego, nowe sposoby generowania komórek produkcyjnych i ich zastosowanie do rekombinowanej produkcji polipeptydów
SG10201913406SA (en) * 2014-07-18 2020-03-30 Celltheon Corp Methods and compositions for expression of polypeptides in a cell
KR102559149B1 (ko) * 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
WO2020260431A1 (en) * 2019-06-28 2020-12-30 F. Hoffmann-La Roche Ag Method for the production of an antibody
US12116578B2 (en) 2019-08-07 2024-10-15 APDN (B.V.1.) 1nc. Methods and systems of PCR-based recombinant adeno-associated virus manufacture
CN112626121B (zh) * 2020-12-29 2024-04-09 苏州博腾生物制药有限公司 三筛选标记的抗体表达载体以及应用
CN113512537A (zh) * 2021-08-19 2021-10-19 长春生物制品研究所有限责任公司 高表达人促卵泡激素的重组cho细胞株及其构建方法

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
JP3051411B2 (ja) 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6207455B1 (en) * 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
PT1034298E (pt) 1997-12-05 2012-02-03 Scripps Research Inst Humanização de anticorpo murino
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
EP1112353A2 (en) 1998-09-16 2001-07-04 Nexia Biotechnologies, Inc. Recombinant protein production in urine
KR20000046969A (ko) 1998-12-31 2000-07-25 이선경 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
EP2270148A3 (en) 1999-04-09 2011-06-08 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
BR0014480A (pt) 1999-10-04 2002-06-11 Medicago Inc Método para regular a transcrição de genes estranhos
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
CA2393869A1 (en) 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
CZ2008595A3 (cs) * 2000-02-24 2017-05-03 Washington University Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci
IL151853A0 (en) 2000-04-11 2003-04-10 Genentech Inc Multivalent antibodies and uses therefor
AU2001261628A1 (en) * 2000-05-16 2001-11-26 Euroceltique S.A. Cd28 synthebody for the modulation of immune responses
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
JP4290423B2 (ja) 2000-10-06 2009-07-08 協和発酵キリン株式会社 抗体組成物を生産する細胞
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
MXPA03004313A (es) 2000-11-17 2007-02-27 Hematech Llc Expresion de inmunoglobulinas xenogenas (humanas) en ungulados transgenicos, clonados.
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
EA007388B1 (ru) 2001-01-29 2006-10-27 Идек Фармасьютикалз Корпорейшн Модифицированные антитела и способы применения
CN1533438A (zh) 2001-06-08 2004-09-29 �����Ŵ��Ƽ���˾ 在植物生产蛋白质的方法
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2462628C (en) * 2001-10-02 2019-08-20 Institut Clayton De La Recherche Restricted expression lentiviral vectors
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
ATE420964T1 (de) 2001-11-16 2009-01-15 Biogen Idec Inc Polycistronische expression von antikörpern in cho zellen
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030215858A1 (en) 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
AU2003236015A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
WO2003084569A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
MXPA04009924A (es) 2002-04-09 2005-07-01 Kyowa Hakko Kogyo Kk Celulas de genoma modificado.
DE60336548D1 (de) 2002-04-09 2011-05-12 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PL212899B1 (pl) 2002-12-16 2012-12-31 Genentech Inc Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku
NZ541458A (en) 2003-01-07 2006-04-28 Symphogen As Method for manufacturing recombinant polyclonal proteins
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
JP4685764B2 (ja) * 2003-04-10 2011-05-18 アボット バイオセラピューティクス コーポレイション 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk HYBRID PROTEIN COMPOSITION
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
PT2380910E (pt) 2003-11-05 2015-11-26 Roche Glycart Ag Moléculas de ligação ao antigénio com uma maior afinidade de ligação ao recetor de fc e uma melhor função efetora
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
US7569362B2 (en) 2004-03-15 2009-08-04 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
ES2403055T3 (es) 2004-04-13 2013-05-13 F. Hoffmann-La Roche Ag Anticuerpos anti-P-selectina
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
JP2008539792A (ja) 2005-05-18 2008-11-20 バイオファクチューラ・インコーポレーテッド トランスフェクト細胞の代謝選択のための組成物および方法
DE602006021335D1 (de) 2005-10-21 2011-05-26 Hoffmann La Roche Methode zur rekombinanten expression eines polyeptids
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
EP2059533B1 (en) 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
EP2099914A1 (en) 2006-12-22 2009-09-16 F. Hoffmann-Roche AG Selection method
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100999732A (zh) 2006-12-30 2007-07-18 北京济普霖生物技术有限公司 一种利用动物乳腺生产抗人cd20单克隆抗体的方法
TW200907059A (en) 2007-03-30 2009-02-16 Abbott Lab Recombinant expression vector elements (rEVEs) for enhancing expression of recombinant proteins in host cells
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
ATE535607T1 (de) 2007-06-29 2011-12-15 Hoffmann La Roche Promotor
BRPI0818165B8 (pt) 2007-10-12 2021-05-25 Hoffmann La Roche método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
WO2009080720A1 (en) * 2007-12-21 2009-07-02 Novartis Ag Mammalian expression vector
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
CN101550425B (zh) 2008-03-31 2011-03-30 北京大学 一种可调控的肝损伤动物模型的制作方法及其专用载体
EP3456192A1 (en) 2008-06-27 2019-03-20 Merus N.V. Antibody producing non-human mammals
CA2734340C (en) 2008-08-28 2019-03-05 Novartis Ag Cell surface display of polypeptide isoforms by stop codon readthrough
GB0903207D0 (en) 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
CN102369214B (zh) 2009-04-07 2019-04-12 罗氏格黎卡特股份公司 三价、双特异性抗体
KR101431319B1 (ko) 2009-05-27 2014-08-20 에프. 호프만-라 로슈 아게 삼중특이성 또는 사중특이성 항체
JP4547643B1 (ja) * 2009-06-05 2010-09-22 東洋紡績株式会社 クローニングに最適化された発現ベクター
JP4525863B1 (ja) 2009-06-05 2010-08-18 東洋紡績株式会社 高生産性細胞の樹立のための発現ベクター及び高生産性細胞
CN101596316A (zh) 2009-06-12 2009-12-09 长沙新生康源生物医药有限公司 表达FoxMlsiRNA的重组腺病毒及其在肿瘤治疗和预防中的应用
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
US20120231449A1 (en) * 2009-09-18 2012-09-13 Selexis S.A. Products and methods for enhanced transgene expression and processing
JP5506339B2 (ja) 2009-11-19 2014-05-28 三菱重工業株式会社 方向制御装置および方向制御方法
KR20130049196A (ko) * 2010-08-05 2013-05-13 에프. 호프만-라 로슈 아게 항-mhc 항체 항-바이러스성 사이토카인 융합 단백질
BR112013014949B1 (pt) * 2010-12-15 2021-12-28 Inter-University Research Institute Corporation Research Organization Of Information And Systems Métodos para a produção de uma proteína de interesse e para a obtenção de uma suspensão de células cho capaz de sobreviver e proliferar em um meio sem soro que produz uma proteína de interesse
PL2794878T3 (pl) * 2011-12-22 2020-07-27 F.Hoffmann-La Roche Ag Organizacja wektora ekspresyjnego, nowe sposoby generowania komórek produkcyjnych i ich zastosowanie do rekombinowanej produkcji polipeptydów
JP6708548B2 (ja) 2013-12-20 2020-06-10 ノバルティス アーゲー 新規真核細胞および目的の生成物を組換え発現させるための方法

Also Published As

Publication number Publication date
JP2017060519A (ja) 2017-03-30
CN107881196A (zh) 2018-04-06
US20210054083A1 (en) 2021-02-25
JP2021072867A (ja) 2021-05-13
HRP20200744T1 (hr) 2020-07-24
EP2794878B1 (en) 2020-03-18
BR112014012667A2 (pt) 2018-10-09
RU2017127208A3 (pl) 2021-04-02
RU2628703C2 (ru) 2017-08-21
CA3125875A1 (en) 2013-06-27
KR102080356B1 (ko) 2020-02-24
RU2014129729A (ru) 2016-02-20
JP2015502165A (ja) 2015-01-22
KR20140113915A (ko) 2014-09-25
JP2019071903A (ja) 2019-05-16
EP2794878A1 (en) 2014-10-29
ES2791758T3 (es) 2020-11-05
EP3816284A1 (en) 2021-05-05
HK1250743A1 (zh) 2019-01-11
SI2794878T1 (sl) 2020-07-31
RU2756106C2 (ru) 2021-09-28
SG11201403223PA (en) 2014-07-30
HK1203546A1 (en) 2015-10-30
SG10201805622QA (en) 2018-08-30
KR20200133827A (ko) 2020-11-30
KR102184059B1 (ko) 2020-11-30
MX2014007360A (es) 2014-08-01
JP7057456B2 (ja) 2022-04-19
US20140370547A1 (en) 2014-12-18
CN104114701A (zh) 2014-10-22
US9963511B2 (en) 2018-05-08
BR112014012667A8 (pt) 2017-06-20
RU2017127208A (ru) 2019-02-14
KR102280111B1 (ko) 2021-07-21
SG10201601882PA (en) 2016-04-28
KR20200008017A (ko) 2020-01-22
WO2013092723A1 (en) 2013-06-27
MX355625B (es) 2018-04-25
US10882910B2 (en) 2021-01-05
US20180334505A1 (en) 2018-11-22
CA2853955C (en) 2021-09-28
CA2853955A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
HK1200848A1 (en) Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
IL271870B (en) Factor viii chimeric and hybrid polypeptides and methods of using them
HRP20190484T1 (hr) Pripravci stanične kulture i postupci proizvodnje polipeptida
HK1250743A1 (zh) 表達載體組織、新的生產用細胞產生方法及其在重組產生多肽中的用途
IL260045B (en) Polypeptide structures and their uses
PL2836511T3 (pl) Polipeptyd przydatny w adoptywnej terapii komórkowej
IL222454B (en) A process for the production of recombinant polypeptides
HK1209651A1 (en) Cells for producing recombinant iduronate-2-sulfatase -2-
IL222453B (en) A process for the production of recombinant polypeptides
SG11201402139UA (en) High mast2-affinity polypeptides and uses thereof
HK1221977A1 (zh) 用於產生供生產重組蛋白的哺乳動物生產細胞的物品和方法
HK1210193A1 (en) Method for the production of polypeptides in the periplasm of prokaryotic cells
TH1401000758B (th) วัสดุไวปฏิกิริยาขั้วไฟฟ้าบวกสำหรับแบตเตอรี่โซเดียมและวิธีการผลิตวัสดุไวปฏิกิริยานี้